Radiopharmaceuticals in Nuclear Medicine Market Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
- Get link
- X
- Other Apps
Radiopharmaceuticals in Nuclear Medicine Market |
The report's market dynamics section elaborates on the
current market drivers, restraints, challenges/risks, and upcoming
opportunities. This section is likely to be of great interest to any company's
strategists and new product development team. The study segments the global
Radiopharmaceuticals in Nuclear Medicine market and provides market size in
terms of revenue and/or sales. This information is divided into regions and
then countries. The information is gathered through in-depth primary interviews
with industry experts all over the world. Our sample reports contain detailed
methodology. These market estimates are also influenced by the most recent
social, political, and economic changes, as well as current market dynamics
affecting the Radiopharmaceuticals in Nuclear Medicine market.
The market's key players are focusing on obtaining
approvals, which is expected to drive Radiopharmaceuticals
in Nuclear Medicine market growth over the forecast period. NorthStar
Medical Radioisotopes, LLC, for example, received FDA approval in February 2018
for its RadioGenix System, an innovative, high-tech radioisotope separation
platform indicated for use in producing widely-used medical radioisotope
technetium-99 (Tc-99m) from NorthStar's non-uranium-based molybdenum-99
(Mo-99).
Following the COVID-19 outbreak in December 2019, the
disease has spread to over 100 countries around the world, prompting the World
Health Organization to declare it a public health emergency. According to the
World Health Organization, the coronavirus (COVID-19) manifestation has
resulted in more than 27.8 million infected individuals worldwide as of
September 2020.
- Get link
- X
- Other Apps
Comments
Post a Comment